NVX 508

Drug Profile

NVX 508

Alternative Names: NVX-508

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuvOx Pharma
  • Class Antianaemics
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Sickle cell anaemia

Most Recent Events

  • 28 Aug 2017 NuvOx and the University of Pittsburgh plan a phase Ib trial in Sickle cell disease by end of summer 2017
  • 28 Feb 2016 Preclinical trials in Sickle cell anaemia in USA
  • 14 Feb 2016 NVX 508 receives Orphan Drug status for Sickle cell anaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top